David Ricks, Eli Lilly CEO (Al Drago/Bloomberg via Getty Images)
Lilly CEO raises concerns about Novo-Catalent buy, calling the Novo Nordisk deal ‘unusual’
Eli Lilly has expressed reservations about the Novo-Catalent deal and its potential impact on the wider manufacturing industry.
“Given the nature of this transaction …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.